Replies to post #138451 on Biotech Values

[DewDiligence]

BIIB—Since all patients in the extension trial are treated with active therapy, it will be difficult to assess the rate of malignancies relative to a background rate as per a placebo arm and will be difficult to draw causality, the person familiar noted.

Translation: There is no story here, but I was on editorial deadline and had to write something.

There was no delta in BG-12 cancer rates relative to placebo in the DEFINE and CONFIRM studies.